Elbasvir

Routes
Oral (PO)
Half-Life (t½)
PO: 24h
Formula
C49H55N9O7
Molecular Weight
882.02 g/mol
PubChem CID
71661251
Aliases
Zepatier (with grazoprevir), MK-8742

Pharmacological Mechanism

HCV NS5A inhibitor — Zepatier component (50 mg elbasvir + 100 mg grazoprevir, once daily for genotype 1 or 4 HCV). Modest CYP3A4 substrate; not a strong inhibitor at clinical doses. The combo is taken with or without ribavirin depending on cirrhosis status and prior treatment failure. PK (Zepatier label, 50 mg PO qd SS): Cmax 121 ng/mL, AUC 1920 ng·h/mL, Tmax 3 h (range 3-6), t½ 24 h, F 32%. High-fat meal effect on elbasvir is modest (~15%). Steady state by ~6 days. CYP3A4 substrate; strong inhibitors require dose adjustment.

Half-Life & Elimination Curve (PO: 24h)

100%50%25%12.5%0%0h0×t½24h1×t½48h2×t½3d3×t½4d4×t½5d5×t½0×t½ (0h): 100% remaining (~46.6 µg/L)1×t½ (24h): 50% remaining (~23.3 µg/L)2×t½ (48h): 25% remaining (~11.7 µg/L)3×t½ (3d): 12.5% remaining (~5.83 µg/L)4×t½ (4d): 6.3% remaining (~2.92 µg/L)5×t½ (5d): 3.1% remaining (~1.46 µg/L)
Plasma (PO)t½ Decay (24h)
  • 0×t½0h100% (46.6 µg/L)
  • 1×t½24h50% (23.3 µg/L)
  • 2×t½48h25% (11.7 µg/L)
  • 3×t½3d12.5% (5.83 µg/L)
  • 4×t½4d6.3% (2.92 µg/L)
  • 5×t½5d3.1% (1.46 µg/L)
Elimination t½24h (PO)
Rate Constant (ke)0.0289 h⁻¹
Time to Peak (Tmax)6.05h
Est. Peak (Cmax)46.6 µg/L
Clearance (CL)8.32 L/h
97% Washout (5×t½)5d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References